These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 23060103)
1. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort. Pereira VC; Malfetano FR; Meira ID; Souza LF; Liem AM; Maiolino A; Alves-Leon SV Arq Neuropsiquiatr; 2012 Oct; 70(10):774-9. PubMed ID: 23060103 [TBL] [Abstract][Full Text] [Related]
2. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877 [TBL] [Abstract][Full Text] [Related]
3. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992 [TBL] [Abstract][Full Text] [Related]
4. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
5. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy. Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454 [TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of responders to interferon therapy for relapsing MS. Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396 [TBL] [Abstract][Full Text] [Related]
7. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350 [TBL] [Abstract][Full Text] [Related]
10. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767 [TBL] [Abstract][Full Text] [Related]
11. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis. Becker RV; Dembek C J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808 [TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate for the treatment of multiple sclerosis. Wolinsky JS Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570 [TBL] [Abstract][Full Text] [Related]
13. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Galetta SL; Markowitz C; Lee AG Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057 [TBL] [Abstract][Full Text] [Related]
16. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825 [TBL] [Abstract][Full Text] [Related]
17. Natalizumab for relapsing remitting multiple sclerosis. Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773 [TBL] [Abstract][Full Text] [Related]
18. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]